CTIM-15. EO2401 PEPTIDE IMMUNOTHERAPY + NIVOLUMAB +/- BEVACIZUMAB IN FIRST RECURRENT GLIOBLASTOMA: TREATMENT STRATEGY OPTIMIZATION IN THE PHASE 1/2 STUDY EOGBM1-18 / ROSALIE (NCT04116658)

Le résumé fourni par la source

Abstract EO2401, composed of peptide sequences from gut bacteria that cross-react with glioblastoma tumor-associated antigens (IL13Rα2, BIRC5/survivin, and FOXM1) plus a helper peptide, was administered to HLA-A2 positive patients with first progression of a glioblastoma requiring ≤ 2 mg dexamethasone/day. Mature data from cohorts-2a/2b (EO2401/nivolumab, n=44) and 3 (EO2401/nivolumab/bevacizumab, n=26) are provided. Ex vivo tetramer-staining on PBMCs demonstrated expansion of CD8 T-cells specific for EO2401 TAAs in 84% of tested patients for cohort-2a/2b and in 92% for cohort-3. Adverse events were limited to those expected for nivolumab and bevacizumab, as well as local site reactions to EO2401 (96% events grade 1-2). Improved outcomes were observed for cohort-3 (median follow-up 33.5 months) versus 2a/2b (median follow-up 25.0 months) including: time of study therapy (4.8 vs 2.3 months), median PFS (4.8 vs 1.9 months), ORR (38% vs 14%) and median OS (12.1 vs 10.8 months). Median OS for patients who underwent second surgery prior to EO2401 start vs no surgery were 18.5 vs 8.5 months for cohort-3 and 11.1 vs 10.2 months for cohort-2a/2b. Multivariable Cox regression analyses revealed that OS for cohort-3, but not cohort 2a/2b was associated with second surgery (HR=0.08, 95%-CI 0.01–0.75, p=0.027), gender (HR=10.2, 95% CI 2.17–48.3, p=0.003) and baseline dexamethasone use (HR=9.35, 95%-CI 2.03–43.1, p=0.004) whereas MGMT methylation status and tumor size was not. For external validation, application of the same model to the CM-143 dataset (1st glioblastoma progression randomized to nivolumab [n=83] vs bevacizumab [n=77]) revealed no associations with OS for bevacizumab while MGMT status (HR=1.95, 95%-CI 1.12–3.17, p=0.007) and baseline corticosteroid use (HR=2.30, 95%-CI 1.42–3.71, p=0.001) associated with OS for nivolumab. Our data indicate that a randomized trial further evaluating EO2401 is warranted and also suggest that surgery prior to triplet therapy, along with baseline dexamethasone use, should be further investigated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.